Ovagen
A synthetic tripeptide bioregulator (Glu-Asp-Leu) from the Khavinson system, studied for liver tissue support, hepatoprotection, and gastrointestinal health.
What is Ovagen?
Ovagen is a synthetic tripeptide consisting of glutamic acid, aspartic acid, and leucine (Glu-Asp-Leu, or EDL), developed as part of Vladimir Khavinson's bioregulator peptide system. It is classified as a Cytogen — a lab-synthesized short peptide designed to mirror the regulatory effects of peptides naturally found in liver tissue. Its natural-extract counterpart is Svetinorm. Like other Khavinson bioregulators, Ovagen is proposed to penetrate cell nuclei and modulate gene expression in a tissue-specific manner, targeting hepatocytes and gastrointestinal cells.
What Ovagen Is Investigated For
Ovagen is a synthetic Khavinson tripeptide (Glu-Asp-Leu) marketed for liver tissue support, hepatoprotection, gastrointestinal mucosal protection, and mitigation of liver fibrosis and oxidative stress in hepatocytes. Even by the standards of the Khavinson bioregulator program, Ovagen sits at the thinner end of the evidence distribution — there are no PubMed-indexed studies of the EDL sequence itself, and every mechanistic or clinical claim is extrapolation from work on other short peptides in the Khavinson lineage (Vesugen, Epithalon, Pancragen) plus marketing material from the Khavinson Peptides product line. No blinded randomized trials exist for any defined hepatic indication (NAFLD/MASLD, viral hepatitis, cirrhosis), oral bioavailability of intact EDL has not been measured, and independent Western-laboratory replication is absent. Russian dietary-complex registration is not equivalent to drug approval and should not be mistaken for evidence of efficacy or safety. The responsible framing: a theoretical bioregulator with no peptide-specific human or animal data.
History & Discovery
Ovagen is the synthetic Cytogen counterpart to Svetinorm, a liver-derived peptide complex (Cytomax) developed within Vladimir Khavinson's bioregulator program at the St. Petersburg Institute of Bioregulation and Gerontology. The Khavinson school's working method — fractionate animal-tissue extracts into shorter and shorter peptides, then synthesize a single defining sequence claimed to retain organ-tropic activity — produced the tripeptide Glu-Asp-Leu (EDL) as the proposed active fragment representing liver-tissue regulation. In the published-evidence ranking of the Khavinson bioregulators, Ovagen is at the thinner end. Unlike Vesugen, Livagen, or Epithalon, EDL has essentially no peptide-specific PubMed footprint as an experimental subject — its mechanistic claims rest on extrapolation from broader Khavinson short-peptide work rather than on its own cell-culture or animal studies. The peptide reaches Western users almost entirely through the Russian Khavinson Peptides oral capsule line (where it is positioned as a liver-support functional food) and through small-volume research-chemical channels. Independent characterization of the EDL sequence by laboratories outside the Khavinson orbit is, as of this writing, absent.
How It Works
Ovagen is a small three-amino-acid peptide proposed to enter liver cells and reach the nucleus, where it may influence which genes are active. The goal is to support the liver's natural repair and detoxification processes, particularly as these functions decline with age.
Ovagen (Glu-Asp-Leu) is proposed to penetrate hepatocyte membranes via POT family peptide transporters (PEPT1, PEPT2) and interact directly with DNA and histone proteins in the nucleus. Based on the broader Khavinson short-peptide framework, it is theorized to bind AT-rich DNA sequences in regulatory regions of liver-specific genes, promoting chromatin decondensation and reactivating genes involved in protein synthesis, antioxidant defense, and hepatocellular repair. However, these specific molecular interactions have not been experimentally validated for the EDL sequence — the proposed mechanism is extrapolated from studies on other Khavinson bioregulators like Vesugen (KED) and Epithalon (AEDG).
Evidence Snapshot
Human Clinical Evidence
None indexed in PubMed. No human clinical trials specific to Ovagen or the EDL tripeptide have been published in peer-reviewed literature accessible through Western databases.
Animal / Preclinical
None indexed in PubMed for Ovagen specifically. The theoretical basis rests on broader Khavinson research demonstrating that short peptides (2-4 amino acids) can penetrate cell nuclei, bind DNA, and modulate gene expression in tissue-specific ways.
Mechanistic Rationale
Weak for Ovagen specifically; moderate for the broader peptide class. The Khavinson framework of short peptide bioregulation has published evidence for related peptides (Vesugen, Pancragen, Epithalon), but the EDL sequence lacks independent mechanistic studies.
Research Gaps & Open Questions
What the current literature has not yet settled about Ovagen:
- 01Peptide-specific preclinical studies — Ovagen has no PubMed-indexed studies of the EDL sequence itself; all mechanistic claims are extrapolated from related Khavinson short peptides.
- 02Independent replication outside the Khavinson research program — even the broader framework claims have not been verified by Western laboratories at the EDL-specific level.
- 03Human pharmacokinetics — oral bioavailability, hepatocellular distribution, and clearance of EDL are uncharacterized despite oral administration being the dominant commercial form.
- 04Blinded randomized controlled trials in any liver indication — there are no clinical trials of Ovagen for NAFLD/MASLD, viral hepatitis, alcoholic liver disease, or any other defined hepatic condition.
- 05Tissue-specificity mechanism — why this particular tripeptide should target hepatocytes rather than other tissue types lacks any direct experimental validation for the EDL sequence.
- 06Long-term safety — no chronic-dosing data exists in any species at any dose.
Forms & Administration
Ovagen is available in capsule and sublingual formats. Capsule protocols typically involve 1-2 capsules daily for 10-30 days. All peptides should only be used under the guidance of a qualified healthcare provider. Never self-administer without clinician oversight.
Dosing & Protocols
The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.
Typical Range
Khavinson-line oral capsules are dosed at roughly 200 mcg of peptide per capsule, taken as 1–2 capsules daily. There is no widely circulated injectable Ovagen protocol in the gray market because the peptide is overwhelmingly sold as an oral product.
Frequency
Once daily during a course is the canonical cadence, sometimes split into morning and evening for the oral capsule.
Timing Considerations
No specific timing requirements: can be administered at any time of day, with or without food, and is not tied to exercise timing. Consistency matters more than the specific clock — dose at roughly the same time each day (or same day each week, for weekly protocols) to keep exposure steady.
Cycle Length
10-day courses repeated 2–4 times per year is the canonical Khavinson schedule, with some protocols extending a single course to 20–30 days. Continuous chronic dosing is not part of the published convention.
Protocol Notes
Ovagen is essentially an oral-only Khavinson product in commercial reality. Reconstitution and injectable protocols, where they exist, are forum constructions rather than clinical conventions. The peptide has no PubMed-indexed pharmacokinetic characterization at all, so even oral bioavailability claims rest on extrapolation from related short peptides (notably Livagen, where intestinal-peptidase resistance has been more directly studied). No Western clinician operates a Ovagen protocol. Anyone using it outside of Russia is relying on Khavinson Peptides marketing material and forum convention rather than independently anchored guidance. Be honest with yourself about what that means for confidence in dose, duration, or expected effect.
Ovagen is not FDA-approved for any indication. Hepatoprotective and GI-support claims significantly exceed what controlled clinical evidence — which for Ovagen specifically is essentially nonexistent — would support. It should not be used as a substitute for evaluation of hepatic or gastrointestinal disease by a qualified clinician.
Timeline of Effects
Onset
No characterized onset profile, in part because no controlled clinical or peptide-specific preclinical work exists. The mechanism the Khavinson framework invokes (chromatin remodeling, gene reactivation in hepatocytes) is structural and not expected to produce acute symptomatic effect.
Peak Effect
Khavinson protocols measure outcomes at the end of a 10–20 day course. For Ovagen specifically, no peptide-specific outcome time-courses have been published.
After Discontinuation
No documented withdrawal or rebound. The framework's standard claim is gene-expression remodeling persisting after dosing ends, but for Ovagen specifically this persistence has not been directly demonstrated.
Common Questions
Who Ovagen Is NOT For
- •Active or recent malignancy — proposed mechanism (gene reactivation, hepatocellular protein synthesis stimulation) sits in proliferative biology; in the absence of safety data, caution is warranted.
- •Active liver disease requiring clinical management — Ovagen should not be substituted for or layered onto hepatology care without clinician oversight.
- •Pregnancy — no reproductive-toxicology data; not recommended.
- •Breastfeeding — no data on transfer or infant exposure.
- •Pediatric use — no pediatric safety or developmental data.
- •Known hypersensitivity to peptide preparations or to capsule excipients in commercial Khavinson-line products.
Drug & Supplement Interactions
There are no documented clinical drug interactions for Ovagen because there are no human pharmacovigilance studies and no peptide-specific pharmacokinetic data. What follows is theoretical. The most plausible mechanistic concerns are with hepatotoxic medications (high-dose acetaminophen, methotrexate, isoniazid, certain antiretrovirals and antiepileptics) where the peptide is sometimes positioned as 'protective' on the strength of broader Khavinson framework claims, but where no human evidence supports that protective effect — and a false sense of protection could discourage appropriate dose monitoring or hepatology follow-up. Concurrent use during anti-cancer chemotherapy is mechanistically discouraged on the same logic that applies to other bioregulators claiming to reactivate cellular gene expression. Patients on any regular medication, particularly those with abnormal liver function tests, should disclose Ovagen use to their prescribing clinician.
Safety Profile
Common Side Effects
Cautions
- • Not FDA-approved
- • No PubMed-indexed safety or efficacy data specific to Ovagen
- • Quality and purity vary significantly by source
- • Should be used under clinician guidance
What We Don't Know
No Western or PubMed-indexed clinical trial data exists for Ovagen specifically. Safety claims are extrapolated from the broader Khavinson bioregulator program. Long-term effects are unknown.
Legal Status
United States
Not FDA-approved for any indication. Not recognized as a dietary supplement ingredient and not on the FDA's compounding-eligible peptide list. Available primarily as personally imported Russian-market oral capsule product, which is not an authorized clinical channel.
International
Sold in Russia under the Peptides.ru / Khavinson Peptides brand as an oral peptide bioregulator capsule, positioned as a dietary supplement / functional food rather than a registered prescription medicine. Not authorized as a medicine by EMA, MHRA, TGA, or Health Canada.
Sports & Competition
Not specifically named on the WADA Prohibited List. Because no governmental regulatory health authority approves Ovagen for human therapeutic use, it can reasonably be read as falling under WADA's S0 catch-all category. Athletes subject to WADA code should treat it as prohibited, particularly in any injectable form.
Regulatory status changes over time. Verify current local rules with a qualified professional.
Myths & Misconceptions
Myth
Ovagen is well-studied as a liver bioregulator.
Reality
It is one of the least directly studied peptides in the Khavinson lineup, with no PubMed-indexed studies of the EDL sequence itself. The 'evidence base' for Ovagen is essentially extrapolation from work on other short peptides plus marketing material from the Khavinson Peptides product line.
Myth
Ovagen treats fatty liver disease, hepatitis, or cirrhosis.
Reality
There are no clinical trials of Ovagen for any defined hepatic condition. Standard hepatology care for NAFLD/MASLD, viral hepatitis, and cirrhosis is dramatically better evidenced and should not be replaced or delayed in favor of an unstudied peptide.
Myth
Because Ovagen is the synthetic version of Svetinorm, it has the same evidence base.
Reality
Svetinorm is itself a thinly published Cytomax preparation. Even on the generous interpretation that synthetic Cytogens inherit the evidence of their parent extracts, Svetinorm's footprint does not meaningfully extend the case for Ovagen.
Myth
Oral Ovagen is reliably bioavailable to the liver.
Reality
Oral bioavailability of EDL has not been measured. Inferring liver-specific exposure from the fact that some short peptides survive intestinal digestion is an unsupported leap.
Published Research
4 studiesPeptide Regulation of Gene Expression: A Systematic Review.
Gene expression in human mesenchymal stem cell aging cultures: modulation by short peptides.
Peptide Regulation of Cell Differentiation.
Short Peptides Regulate Gene Expression.
Quick Facts
- Class
- Bioregulator Peptide
- Tier
- F
- Evidence
- Limited
- Safety
- Limited Data
- Updated
- Apr 2026
- Citations
- 4PubMed
Also known as
Tags
Peptide Families
Related Goals
Evidence Score
Clinical Trials
View Clinical TrialsLinks to ClinicalTrials.gov for reference. Listing does not imply endorsement.